Interview with the CEO of Actoverco
According to the public relations of Actover Group, Nahaleh Naraghi is the CEO of Actoverco. Actoverco is a leading company in the field of producing high quality drugs in accordance with the latest international standards.
Four great achievements
efforts of the children of Iran in the Actover Pharmaceutical Group, four great achievements in the current situation are presented as a drop from the boundless sea of service to the noble people of our country.
Unveiling of 3 new drugs of Actoverco Company among the neurology group
On December 26, 2019, during a glorious ceremony attended by more than 180 psychiatrists and neurologists, three new drugs of Actoverco Company were officially unveiled.
Visit of neurologists and psychologists from Actoverco Pharmaceutical Factories
Actover Group, on the occasion of Doctor’s Day, hosted a group of prominent neurology and psychologist professors of Tehran on Thursday, August 22.
Signing agreement of cooperation and establishment of a new innovation center in the Actoverco company
Signing agreement of cooperation for the establishment of the “Actotech Innovation Center” and the beginning of the official knowledge-based activities in the Actoverco company was held in the presence of the Vice President for Science and Technology.
We did not shout a slogan, we acted
The CEO of the Actover Pharmaceutical Group at the opening ceremony of the new Actoverco Solid Drug Production Plant said: “Currently, there are about 3000 people working in the Actover Pharmaceutical Group, 90% of whom are under 40 years old.”
Another big step of Iran in the production of anti-cancer drugs
The largest factory for the production of anti-cancer drugs in the Middle East, as well as the biotechnology department of the pharmaceutical group, was put into operation in Alborz with the presence of the Minister of Health.
Actoverco received 90.8 million Euros of governmental currency in the first half of this year
The CEO of Actoverco said: “This Company has received about 90 million and 800 thousand Euros of governmental currency in the first 6 months of the year.”
With the lifting of sanctions, many announced their readiness to work with “Actoverco
We have a program for production of Rituximab and Bevacizumab drugs for cancer patients, ophthalmologists, etc. These drugs are very expensive due to their high technical knowledge, and from next year, we will also produce the raw materials for these drugs ourselves.
- « Previous
- 1
- 2